20 Novembre 2026

Psicologia Punto One | Psicologia e Psicologi nel Web

Menu

Menu

SCHEDA SCIENTIFICA2026Altra ricerca

Next-Generation Psychedelic Drug Development.

Cameron LP, Johnson MW, Murnane KS, Rasenick MM, Nichols CD

ACS chemical neuroscience · 2026

Abstract originale

Psychedelic medicine has gained rapid popularity for the treatment of a variety of neuropsychiatric disorders, including depression, anxiety, and post-traumatic stress disorder. As novel psychedelic analogues and treatment regimes emerge, increasing numbers of variables are being tested. Here, we review various approaches and considerations for novel psychedelic therapies, including the strengths and limitations of current assays and models. Finally, we provide guidance and considerations for next-generation psychedelic drug development.

Parole chiave

HallucinogensHumansDrug DevelopmentAnimalsMental Disorders5-HT2ABiotechdrug developmentnonpsychedelic analogspsilocybinpsychedelics5-ht2aPsilocybinPsychedelicsNonpsychedelic Analogs
Leggi il testo integrale originale

Testo estratto dalla pubblicazione: sono esclusi immagini, media, supplementi e parti soggette a diritti distinti.

Next-Generation Psychedelic Drug Development

Psychedelic medicine has gained rapid popularity for the treatment
of a variety of neuropsychiatric disorders, including depression,
anxiety, and post-traumatic stress disorder. As novel psychedelic
analogues and treatment regimes emerge, increasing numbers of variables
are being tested. Here, we review various approaches and considerations
for novel psychedelic therapies, including the strengths and limitations
of current assays and models. Finally, we provide guidance and considerations
for next-generation psychedelic drug development.

Introduction

Psychedelic compounds have taken center stage in modern neuropsychiatric
research. Psilocybin is found naturally occurring in dozens of species
of mushroom and has shown remarkable efficacy in clinical trials for
major depressive disorder,, cancer-related distress,, alcohol use disorder, tobacco use disorder, demoralization in AIDS survivors, and bipolar
II disorder. Its therapeutic effects are
mediated by its active metabolite psilocin, which is a nonselective
serotonin receptor agonist and psychedelic. Moving beyond psychiatry, promising recent research has been conducted
in the field of neurology with positive findings for psilocybin in
the treatment of migraine and cluster headache disorders. The findings for neuropsychiatric disorders are
notable for several reasons. First is the observation that a high
percentage of patients are helped. Response rates demonstrate remission
from these neuropsychiatric disorders in most participants, and clinically
significant improvement in many participants. The second is the persisting
nature of such improvements. Such results are often observed several
months or even more than a year after treatment. Third, such results
are achieved after only a small number of medication administrations,
typically one, two, or three administrations of the psychedelic compound.
Although initial preparatory meetings and follow-up discussion (“integration”)
sessions are conducted, this is still a remarkably small number of
administrations.

Despite this incredible promise, there are several major limitations
to these treatments that will pose barriers to widespread clinical
application upon potential approval by the United States Food and
Drug Administration, the European Medicine Agency, and other regulatory
bodies. Other barriers to adoption of psychedelic therapy involve
both difficulties in the current administration model as well as the
potential for insurance and government payer agencies to approve payment
for what is now poised to be a very expensive treatment with substantial
professional time. The serotonin-releasing agent 3,4-methylenedioxymethamphetamine
(MDMA; an entactogen, but with some overlapping effects with psychedelics)
has shown strong efficacy in the treatment of post-traumatic stress
disorder (PTSD). Recent trials investigating
MDMA for PTSD cost $11,537 per patient, and psychedelic trials will
likely be within this range as well. The
majority of this cost comes from paying medical professionals for
the duration of therapy and dosing sessions. Given that patients who
often need these mental health therapies have lower socioeconomic
status, this costnot to mention the travel costs, many days
off work for several weeks of sessions, childcare, etc.is
not currently conducive to creating an accessible treatment. However,
psychedelic-inspired medications and novel molecular entities may
hold promise to address many of these concerns.

One common definition of a “psychedelic” is a compound
that elicits alterations in perception, cognition, emotions, and sense
of self via activation of 5-HT2AR. For the purpose of this
review, we employ another commonly used definition of “psychedelic”
that broadly describes compounds that elicit such effects regardless
of pharmacological site of action. Here, we discuss several drawbacks
to first-generation psychedelic and related compounds currently under
investigation (e.g., psilocybin, MDMA), and target properties of novel
compounds that may address these limitations.

This Review will attempt to coalesce recent advances in psychedelics
from the standpoint of both research and therapy. The authors also
wish to discuss current impediments and propose potential solutions
that might establish a rationale for psychedelic therapy and chart
a path forward for those who hope to bring it to fruition.

Nonpsychoactive Analogs

First-generation psychedelics
[e.g., psilocybin, lysergic acid diethylamide (LSD), N,N-dimethyltryptamine (DMT), 5-methoxy-N–N-dimethyltryptamine
(5-MeO–DMT), mescaline] are known for their dramatic subjective
effects (Figure
).
Indeed, it is difficult to overstate the magnitude with which patients
often describe such experiences, and how unique and enduring these
effects can be. For example, the construct of “mystical experience”
has been used in the assessment of psychedelic effects. Such effects
involve strong endorsement of elements including senses of unity (e.g.,
feeling at one with the universe), timelessness, spacelessness, ineffability,
and positive mood., The construct of mystical experience
is highly correlated with (and might be identical with) the construct
of “oceanic boundlessness.” By definition, these are not everyday experiences that are easily
characterized. This relates to the often-debated notion and observation
that it is difficult to conduct credible “blinded” research
(in which the participant is kept uninformed as to whether he/she
received an active drug or placebo). Notably,
nonpsychoactive analogs would be able to circumvent these important
blinding confounds that first-generation psychedelics face. Important
for the current discussion is the debate about whether subjective
effects are necessary for therapeutic effects. On one hand, some studies have shown a relationship between
the intensity of subjective effects on the psychedelic administration
session day with long-term therapeutic outcomes. On the other hand, a growing number of studies have shown
in nonhuman animals that analogs of first-generation psychedelic compounds
that may lack or minimize subjective psychoactivity lead to multiple
forms of neuroplasticity,−

with experimental evidence suggesting
postacute therapeutic-type effects in nonhuman behavioral models.,, The use of animal models for
studying psychedelic action and neuroplasticity is described below.

We do not have direct evidence currently regarding whether such
neuroplastic effects occur in humans and, if they do, whether they
contribute to therapeutic effects. Clearly, psychedelic therapy can
result in behavioral plasticity by definition in that we observe behavioral
change (therapeutic learning). We believe that such neuroplastic effects
are at least one component of what might be multiple mechanisms that
underlie the therapeutic potential of first-generation psychedelics.
There is likely some false dichotomy in debates about whether subjective
effects are necessary for therapeutic effects. For example, subjective
experiences and neuroplastic effects might mediate first-generation
psychedelic therapies. In this vein, nonpsychoactive second-generation
analogues of psychedelics, while not requiring psychoactive effects,
could be inducing similar levels of neuroplastic changes through differing
mechanisms that result in therapeutic effects. For example, experience-dependent
plasticity may be a component of classic psychedelic therapeutic mechanism
of action in human patients, but this would be lacking with nonbehavioral
analogues. If this were the case, then it may be conceivable that
such analogues might require different treatment models. These may
include more regular dosing (e.g., every few weeks as needed or else
daily dosing as with typical psychiatric medications). If patients
were able to self-administer these compounds and continue their daily
lives, then this would drastically increase the accessibility of these
medicines. Or, it might be optimal to explicitly pair the administration
of such compounds to learning trials or therapeutic procedures, as
has been explored with the NMDA agonist, d-cycloserine, in the facilitation
of time-limited extinction-based therapies for phobias and other anxiety
disorders. There are, unfortunately,
limited clinical data in humans for nonbehavioral analogues of psychedelics
in the treatment of neuropsychiatric disorders. Only one clinical
trial has been performed to date with a nonbehavioral psychoplastogen,
zalsupindole, by Delix Therapeutics, which showed sustained therapeutic
effects in an MDD phase 1b clinical trial after only one treatment. Further research needs to be performed, however,
to fully understand the potential therapeutic efficacy of nonbehavioral
analogues for factors like dosing and efficacy, which may be compound-specific.

Given the potential for nonpsychoactive analog compounds, it would
be desirable to create second- and third-generation analogs that are
both maximally and selectively neuroplastic (Figure
). If neuroplasticity underlies psychedelics
and psychedelic analogs’ therapeutic effects, then it is unknown
what form or forms of neuroplasticity are important (for example,
dendritic branching versus synaptogenesis), and which human brain
regions are most affected. Nonpsychoactive compounds (third-generation
analogs) could leverage improved information on the therapeutically
functional form or forms of neuroplasticity, and parametric information
on the degree and timing of such effects. Furthermore, it can increase
accessibility for patients, decrease cost, and minimize adverse events
such as having to deal with difficult experiences. Finally, many individuals
would prefer to minimize altered experiences.

Duration of Psychoactive Effects

Regardless of whether
nonpsychoactive compounds have ultimate therapeutic potential, the
best current evidence based on clinical trials is for overtly psychoactive
compounds incorporated into the “psychedelic therapy”
model. Rather than referring to any therapeutic use of psychedelics,
this term refers to a specific model in which relatively high doses
of psychedelics in patients who have been prepared for the experience,
have developed a rapport with the professional support personnel who
will be present with them during the psychedelic session, and follow
(“integration”) sessions are conducted in which the
experience is discussed in the days following the psychedelic administration
session. Patients are encouraged to pay attention to their experience
during the psychedelic administration session and to minimize attention
to the external environment, often with the use of eyeshades and supportive
music during the experience. This model has roots that date back to
the late 1950s. It seems likely that
this model will continue to be used given the strong current evidence,
and given that long-term therapeutic benefits seem to be related to
lessons learned during or in the aftermath of the subjective experience., Although the psychotherapy-coupled model predominates, there is
evidence from several clinical studies that psychedelics can produce
similar therapeutic efficacy in patients without receiving psychotherapy
sessions. Among these are LSD for generalized anxiety and 5-MeO–DMT
for treatment-resistant depression trials, which demonstrated therapeutic
efficacy.,

Despite the apparent therapeutic responses
to high-dose overt psychedelic therapy, the duration of effects is
likely a clinical barrier that might minimize clinical utilization.
As previously outlined, the current treatment model is extremely expensive
and prohibits access. While cost-effectiveness analyses might show
that such an expense is warranted if long-term results are highly
efficacious, it may be a challenge for obtaining payor coverage for
such treatments in countries like the United States. Regardless of
payer coverage, fewer individuals might be willing to engage in such
lengthy treatment sessions. While we still need empirical research
to determine if long-acting compounds like lysergic acid diethylamide
(LSD) might show improved or similar efficacy to moderate-duration
compounds such as psilocybin and MDMA, the fact that psilocybin and
MDMA are more common in modern research compared to LSD (more commonly
used in the 1950s–1970s research) represents at least some
improvement regarding this concern. However, there is substantial
current commercial and clinical interest in compounds that are even
shorter-acting than psilocybin and MDMA, which last approximately
6 and 4 h, respectively. The psychedelic chemist Alexander Shulgin,
for example, expressed interest in the therapeutic potential of 4-HO–DIPT,
a classic psychedelic with a duration of 2–3 h, for use in
psychotherapy. Similarly, there is substantial
interest in the very short-acting classic psychedelics, DMT and 5-MeO–DMT.−

Investigation of not only these but also novel second- and third-generation
compounds, either related to classic psychedelics or to serotonin-releasing
compounds similar to MDMA, yet with shorter durations of action. Will
such short-acting compounds show similar efficacy to longer-lasting
compounds? How might varying subjective experiences provided by different
drugs affect therapeutic outcome? These are empirical questions that
need investigation. Though compounds such as LSD and psilocybin appear
effective, shorter-duration psychedelic compounds may greatly expand
access to psychedelic therapeutics.

Challenging Experiences

Challenging experiences (known
colloquially as “bad trips”) appear to occur occasionally
with classic psychedelic compounds such as psilocybin and LSD., To date, these appear manageable in the vast majority of cases,
and there is some evidence that they may even be clinically beneficial
for some patients. Nonetheless, these
adverse reactions present the potential for problematic occurrences
such as extreme paranoia or confusion leading to accidents. Just because
such potentially dangerous outcomes have not occurred in the highly
managed trials of academic research today does not mean that they
will not occur when widely clinically available and managed by less
highly trained clinicians.

One goal of third-generation psychedelic
drug development, therefore, would be to devise compounds with substantially
lower potential for challenging experiences while maintaining aspects
of subjective effects showing a relationship to therapeutic outcomes
such as mystical experiences. In some sense, MDMA represents such
an example. While MDMA experiences can be difficult, particularly
when addressing trauma, such challenging experiences might be more
likely to involve difficult emotions, such as those involved with
remembering and processing the traumatic experiences and the negative
self-realization that can result from trauma. MDMA is less likely
to lead to anxiety, paranoia, and derealization that can occur with
classic psychedelics, such as psilocybin., However, mystical experience tends to occur more frequently and
with greater profundity with classic (first-generation) psychedelics., Whether the potential for intense mystical experience scores is
inherently tied to an increased likelihood of challenging experiences
is an open empirical question. Current studies are investigating the
use of psilocybin or LSD with MDMA as a means to neutralize these
undesirable experiences. Therefore, the
development of compounds with high potential for mystical experience
with very low potential for challenging experience is a very worthwhile
area for investigation. Overall, the goal would be to create compounds
that result in sessions that are maximally manageable under a broader
range of conditions. Notably, nonpsychoactive analogues of psychedelics
would circumvent the necessity to prevent challenging experiences.

Reliability of Experience

The increased reliability
of mystical experience is an important area of investigation for second-generation
psychedelics. For novel compounds that strive to retain hallucinogenic
properties, maximizing the number of patients who find their psychedelic
experiences to be personally meaningful and insightful is an important
goal. Although maximally supportive conditions produce positive experiences,
these typically occur in most patients in high-dose therapy with classic
psychedelics; they do not occur in all participants. Furthermore, it is possible that nonresponsive patients
have worsening symptoms following unsuccessful treatment, which is
often attributed to their “last resort” not working.
Increasing the rates of these effects at physiologically safe doses
would therefore be an important goal of second-generation psychedelic
drug development. Further, it is likely that placebo-controlled (or
active comparator) double-blind studies will be required, though fully
effective blinding in such studies is difficult to conduct.

Physiological Safety

Aside from increasing safety by
making the psychoactive effects more manageable, safety can be increased
by increasing the physiological safety of the first-generation compounds.
Although classic psychedelics such as psilocybin are remarkable in
their relative physiological safety, they
are not without safety concerns. Because classical psychedelics modestly
and transiently increase blood pressure and heart rate, they can be
a risk factor for individuals who are cardiovascularly compromised.
Indeed, modern clinical trials exclude such individuals, and potential
postapproval clinical use of these compounds is likely to maintain
the same exclusion of such individuals. Therefore, the development
of second- and third-generation psychedelic compounds with less cardiovascular
impact would allow for the expansion of the treatment. This is especially
important when considering the evidence for psilocybin in the treatment
of seriously ill cancer patients, many of whom have compromised cardiovascular,
respiratory, and metabolic function. While MDMA also appears to be
safe for healthy patients, it has greater acute cardiovascular risk
than classic psychedelics such as psilocybin and LSD. Therefore, the
development of second-generation MDMA-like compounds with a safer
cardiovascular profile would enable the treatment of a larger patient
population.

Another domain for potential physiological concern
for first-generation psychedelic compounds regards the agonist activity
that major psychedelics, including psilocybin and LSD, or indirectly
like MDMA, produce at 5-HT2B receptors. Agonist activity at this receptor has been linked mechanistically
and empirically to valvular heart disease. It was this activity and
mechanism that led to the Food and Drug Administration withdrawal
of clinical approval for the diet medication Fen-Phen in the 1990s.
While it would appear that current treatment models that only administer
one to three doses of the psychedelic might not represent clinically
relevant concern for such toxicity, there is a requirement to explore
the need for repeated dosing, especially for treatment-resistant disorders
or for the frequent administration of minimally psychoactive doses
(colloquially known as “microdosing”). While empirical work might ultimately allay concerns about
heart valve damage with psychedelics, these are currently unaddressed
empirical questions that may be parametrically dependent. Therefore,
in the development of second-generation compounds, the elimination
or minimization of agonist activity at 5-HT2B receptors
is an important goal.

In the same vein, other compounds used in psychedelic therapy such
as ibogaine inhibit hERG channels in the heart, potentially leading
to arrhythmias and heart attacks. This
is a common property of many lipophilic drugs; therefore, current
novel psychedelic synthesis strategies have (and should continue to)
minimize interactions with hERG. While one possible approach is using
coadministration of magnesium to mitigate this risk, newer-generation analogues lacking this form of toxicity
should be investigated.

Other 5-HT receptors may be involved in psychedelics’ unwanted
effects. 5-HT1A receptors may be involved for tryptamine
and ergoline psychedelics because those particular chemotypes show
affinity and efficacy for nearly all serotonin receptors. Further,
ergolines like LSD can have appreciable affinity and efficacy at all
monoaminergic GPCRs, particularly dopamine receptors, in addition
to 5-HT receptors. Analogs lacking these
properties would be beneficial. Figure
illustrates several of the common targets of various
psychedelic drugs, and Table
shows the Emax data for each receptor used to generate Figure
.

1Emax Values of Psychedelics at Various
Important CNS Receptors (Reported as Percent of 5-HT Stimulation)

  D1 D2 5-HT1A 5-HT1B 5-HT2A 5-HT2B 5-HT2C

LSD 136.6
82
102.16
100
76.5
70
29

DMT     93.5
  66.02
  103.15

5-MeO–DMT     107
86.8
83.25
66
100.5

Psilocin     58.31
  50.77
  103.77

MDMA         70.41
  195.65

DOI       108
99.32
103.2
114.3

Mescaline     22.22
  81.15
91.1
108.5

aReferences here for Figure
.

Approaches to Development of Next Gen Drugs

Due to
the lack of perceived medicinal value of psychedelics, and their scheduling
as dangerous substances by the DEA, there was very little interest
by the scientific community in general to develop new agonist ligands
for 5-HT2A receptors after 1970. There were two notable
exceptions: Dr. Alexander Shulgin and Dr. David E. Nichols. Dr. Shulgin
began his chemical experimentation with psychedelic chemicals in the
1960s, with several years of experience from Dow Chemical under his
belt. He is credited for the (re)­discovery of MDMA’s behavioral
effects and the development of certain phenethylamine drugs in the
1960s. Throughout his lifetime, he created hundreds of second-generation
psychedelics based upon the classic psychedelics psilocybin, mescaline,
and LSD. He had a DEA license for analytical research to synthesize
novel chemicals that he used primarily to make substituents and analogs
of psychedelics. However, he often sampled the compounds himself in
risky self-experimentation that generally lacked scientific rigor.
Based on his impressions of the effects, he then further generated
additional variants of molecules that he found interesting. Although
he published many of his syntheses in peer-reviewed journals, he ultimately
published two comprehensive books, PiHKAL and TiHKAL, describing the chemicals
he synthesized and their effects.

Dr. Nichols was engaged in
studies to gain insights into how drugs interact with their target
receptor to influence behaviors. Over the course of his career at
Purdue University, Dr. Nichols also created hundreds of novel psychedelics
based on all three known scaffolds. Each of these was designed with
a purpose in mind, to help map key residues in the orthosteric binding
pocket to chemical constituents on the ligand in order to generate
a greater understanding of mechanisms underlying GPCR-ligand interactions.−

Shulgin and Nichols first published together in 1976 and were collaborators
for several years. It is largely the
effort of these two individuals that laid much of the foundation for
modern psychedelic drug discovery and next-generation psychedelics.

Another chemist who played a prominent role in the early chemistry
of psychedelics is Dr. Richard Glennon, who spent his career at Virginia
Commonwealth University. In addition to synthesizing many new 5-HT2A
ligands, he published in 1984
a study demonstrating that the affinity of ligands for the 5-HT2 receptor had a strong positive correlation with behavioral
effects, thus demonstrating that the receptor target of psychedelics
was the 5-HT2 receptor.

Today there are a plethora of entities, both private and public,
involved in psychedelic drug discovery (Figure
). On the public
academic front, there are research groups designing and testing new
agonists to test specific hypotheses of drug/receptor interactions
and effects on downstream signaling and behaviors, as well as designing
synthetic schemes to generate new chemical entities (NCEs), all for
the pursuit of fundamental knowledge. In the private sector, the efforts
are focused on new routes and formulations of existing psychedelics
as well as the development of NCEs to generate intellectual property
(IP) that allow for the advancement of therapies that benefit the
lives of patients within the context of the care model in the United
States and peer societies.

Unfortunately, despite some recent requests for proposals, the
federal governments of many countries, including the United States,
have directly limited resources for funding research that would result
in the discovery of new psychedelic molecules. Schedule I licenses
are required for research with most psychedelics and apply to both
the small quantities required for basic studies and the appreciably
larger amounts needed for clinical trials. Though Schedule I compounds
are defined as drugs, substances, or chemicals with no currently accepted
medical use and a high potential for abuse, psychedelics remain highly
restricted substances, even for research. Several patient and research
advocacy organizations have attempted to work with both the FDA and
DEA toward rescheduling of psychedelics for research purposes, but
this has not yet been effective. Recent positive results in phase
3 trials of MDMA-assisted therapy for PTSD, despite recent FDA concerns
related to inadequate controls, may create new support for rescheduling,
and this will have a positive effect for research. Finally, the Federal
Analog Act of the United States can subject certain novel psychedelic
compounds that are substantially similar to schedule I or II substances
to schedule I treatment when they are intended for human consumption.

With the now widespread acknowledgment and acceptance of the potential
of psychedelics as viable therapeutics for several conditions, there
is now a tremendous financial incentive to develop new intellectually
protected molecules with blockbuster potential. Due to the current
lack of government funding, nearly every academic lab involved in
psychedelic drug discovery has partnered with a private entity. The
promise of these partnerships is funding for basic research and discovery
through licensing agreements or research contracts, with the sponsor
often having first right of refusal or exclusive rights to any IP
resulting from that work, including NCEs.

Although ideal next-generation molecules for therapeutics may already
exist within the hundreds of 5-HT2A receptor agonists already
described in the scientific literature, they are in the public domain,
and there is not much if any IP that can be ascribed to them. It costs
upward of one billion US dollars or more to bring a drug to market, therefore realistically, any new psychedelic
brought through the development pipeline must have IP strongly associated
with it. As major pharmaceutical companies have largely moved away
from internal Research and Development, therapeutic advancement increasingly
relies on acquisitions of assets that have been developed by smaller
entities that have shown promise in early clinical efficacy trials.
As of this writing, no major pharmaceutical company has fully embraced
psychedelic drug discovery campaigns to identify novel molecules with
their own internal program. Rather, large companies have recently
acquired psychedelic drug assets for further clinical development
by purchasing smaller startups that have demonstrated therapeutic
efficacy in Phase II clinical trials. These include AbbVie’s
purchase of Gilgamesh for bretisilocin, Otsuka’s purchase of
Transcend for methylone, and Eli Lilly’s purchase of AtaiBeckley
for 5-MeO–DMT.−

The amount of each purchase has been, remarkably,
approximately in the $1–3 billion range. These purchases underscore
the enthusiasm and potential for this new class of therapeutic.

Academic or industrial aside, the development of novel psychedelics
can essentially be grouped into one of three distinct strategies.
One involves unbiased high-throughput screening (HTS), which has been
the traditional workhorse of lead identification in the pharmaceutical
industry. Either by brute force or virtual screening, real or virtual
ligands are screened against 5-HT2A receptors in cellular
functional assays or virtual docking in silico by
the millions, if not billions. This is an expensive endeavor and is
only employed by a few entities. Another
involves creating libraries of psychedelic analogues using a function-oriented
synthesis approach and assessing the effects on cell structure and
function, rather than receptor engagement directly., A third method, which seems to be employed by most entities, is
to slightly modify existing known psychedelics with known efficacy
to a somewhat different molecule with IP associated with it. For example,
Reunion Neuroscience is developing a prodrug of the known psychedelic
4-OH-DIPT, and Helus is developing deuterated
psilocin. A fourth method is rational
drug design, where analysis of the orthosteric binding pocket of the
5-HT2A receptor is performed in silico and the findings are used to design NCEs that engage certain amino
acid residues in perhaps a different way than known psychedelics.

Drug development in the psychedelic space can also be grouped into
those developing fully behavioral NCEs and those developing nonpsychoactive
analogs of psychedelics. In one camp are those that believe that the
subjective trip is necessary for therapeutic benefit, and in the other,
those that think the two may be dissociated. Within the former, there
are efforts to develop NCEs with similar behavioral effects and duration
to psilocybin but with strong IP associated with them. There are also
efforts to develop short-acting psychedelics under the theory that
it is not the duration of the subjective experience per se that provides therapeutic efficacy but just getting the patient
to a peak subjective experience for a minimal time that provides efficacy.
For example, the primary asset Eli Lilly acquired from AtaiBeckley
is a novel formulation of a classic psychedelic: intranasal 5-MeO–DMT.
Amandala Neuro, a spin-out of AtaiBeckley, is developing a short-acting
intravenous formulation of psilocin that has shown therapeutic efficacy
in a Phase II trial for major depression.

As we are beginning to understand the receptor pharmacology of
psychedelics better from SAR studies,, this has allowed
for the possibility of nonpsychoactive agonists for 5-HT2A receptors, as discussed above. It remains to be seen, however, if
nonpsychoactive 5-HT2A receptor agonists will demonstrate
therapeutic efficacy in larger Phase III clinical trials and eventually
come to market.

Mechanism of Action

Though the development of NCEs
is an active and heavily funded area of research, little is known
about their therapeutic mechanism of action, particularly for nonpsychoactive
analogues. More research has been done to determine the mechanism
of action of classic psychedelic compounds, which may prove to be
useful in understanding the actions of any derivatives.

Without
doubt, the 5-HT2A receptor plays an integral role in the
psychedelic experience.−

Many arguing that the psychedelic
experience is deeply necessary for the therapeutic effects would therefore
argue that 5-HT2A is also a therapeutic target, and the
two cannot be separated. For scientists trying to disentangle the
hallucinogenic and therapeutic effects through development of nonpsychedelic
analogues, the role of the 5-HT2A receptor in mediating
therapeutic responses remains controversial. Further complicating
the matter, rodents have a polymorphism in the orthosteric binding
pocket of 5-HT2A, which results in different dissociation
rates for tryptamine compounds compared to the human 5-HT2A., Nonhuman primates, however, have nearly
identical 5-HT2A sequences to humans (NP_001028138.1, NP_000612.1).
Finally, the 5-HT2A agonist lisuride is not hallucinogenic.

There have been several hypotheses put forward about the therapeutic
mechanisms of action of psychedelics. One hypothesis posits that although
the hallucinogenic aspects of the drug are mediated by the 5-HT2A receptor, the therapeutic actions of psychedelics can be
mediated through activation of a different receptor: likely 5-HT2C or direct binding to TrkB receptors., Recent evidence has failed to replicate the TrkB findings. 5-HT1A and TAAR have also been implicated
in psychedelic actions.−

The notion of multiple receptor involvement is supported
through findings that suggest that 5-HT2A antagonism is
insufficient for blocking the therapeutic effects of psychedelic compounds, although this remains to be validated.

On the other hand, there is more evidence to suggest that the engagement
of 5-HT2A is necessary to achieve therapeutic effects.
Studies using the 5-HT2A receptor antagonist ketanserin
are sufficient for blocking psychedelic-induced growth of cortical
neurons,, as well as
various behaviors reflective of antidepressant efficacy or other therapeutic
effects.−

However, ketanserin is not selective between 5-HT2 receptors in rodents, and it inhibits other receptors involved
in neural function (such as histaminergic and adrenergic systems),
leaving open the possibility of involvement of 5-HT2C or
other targets. A few studies have demonstrated the necessity of 5-HT2A involvement in cortical neuronal growth and therapeutic
responses using a more specific antagonist, M100907 (volanserin).,−

Recently, endeavors using genetic deletion of 5-HT2A receptors in rodents have illustrated the necessity of this receptor
in psychedelic-mediated fear extinction learning, drug extinction
learning, as well as motivated behaviors (in tail suspension test
and sucrose preference test), all of which depend on engagement with
5-HT2A.,, Psychedelic-mediated dendritogenesis and spinogenesis are also blocked
in these animal models, suggesting that engagement of 5-HT2A is necessary., Recent work has suggested that
activation of the intracellular pool of 5-HT2A receptors
may be important for the action of some psychedelic drugs.

Initial studies with nonpsychoactive analogues suggest that engagement
of 5-HT2A receptor activity is also necessary. Antagonist
administration (ketanserin or M100907) is sufficient for blocking
the therapeutic behavioral actions of nonpsychoactive compounds,, although off-target effects cannot be ruled out due to the nature
of ketanserin. More recently, Aarrestad et al. demonstrated that a
third-generation, nonpsychoactive analogue of a psychedelic, tabernanthalog,
is ineffective when administered to 5-HT2A-KO animals.

If action at the 5-HT2A receptor is necessary, there
are a few mechanisms by which agonists can target the same receptor
but have different downstream effects (i.e., hallucinogenic vs not).
The first theory is functional selectivity; the idea that different
agonists cause different conformational changes to the receptor through
differential interactions with amino acid residues in the orthosteric
binding pocket of the receptor, thereby eliciting different downstream
effects. Current evidence suggests that psychedelics and novel analogues
primarily signal through Gq pathways, though this has yet to be fully tested. Interestingly, the on/off
kinetics of various compounds at 5-HT2A receptors do not
predict hallucinogenic properties. A
second theory involves a different type of functional selectivity,
wherein binding of ligands allows signaling through a dimer complex
of 5-HT2A and mGluR2. Work by Gonzalez-Maeso and colleagues
has elegantly demonstrated signaling through this dimer when stimulated
with psychedelic compounds, but not antipsychotic agents. Psychedelics may signal through this dimer interaction,
though nonhallucinogenic analogues do not; this hypothesis has yet
to be tested. Finally, a paper by the Kim lab has demonstrated that
stimulating a psychedelic-responsive ensemble in the mPFC elicits
anxiolytic properties without a head-twitch response behavior, suggesting
there are different brain regions responsible for therapeutic versus
hallucinatory effects of these compounds. From a drug discovery standpoint, it is possible that the 5-HT2A receptor responds differently to psychedelic compounds depending
on proteins in its immediate environment. This has been documented
for several receptor/G-protein pairs based on their localization in
the membrane microdomains (i.e., lipid rafts)., This could be via direct or indirect (downstream) interactions after
5-HT2A receptor activation. For example, if hallucinatory
effects function through receptor dimerization, perhaps this only
occurs in some brain regions (i.e., claustrum) but not others (i.e.,
mPFC). In this way, nonpsychoactive analogues of psychedelics may
be able to target these distinct differences or engage downstream
targets. The differences in 5-HT2A activation across brain
regions are an important area of research for elucidating optimal
drug targets.

Though necessary, nonpsychoactive psychedelic analogues can have
decreased activity as measured by canonical Gq signaling downstream
of 5-HT2A receptors compared to their psychedelic parent
compounds. Given that 5-HT2A is the most highly expressed
excitatory 5-HT receptor in the brain,−

it is possible that even with
reduced activity, the sheer number of receptors activated is enough
to elicit a therapeutic response.

One hypothesis that needs to be rigorously tested is whether nonpsychoactive
analogs are just “weaker psychedelics.” A sufficient
amount of 5-HT2A activation may be achieved to elicit therapeutic
responses (cortical neuron growth, increased behavioral motivation),
without eliciting perceptual effects. A recent study by Wallach et
al. concludes that an activation of 70% or greater at the Gq pathway
is necessary for behavioral effects. This
work was conducted in immortalized cell lines and should be further
investigated in neurons. In unpublished work, pilot attempts to answer
this question in SH-SY5Y cells have yielded similar but differing
results. In the same vein, microdosingtaking
small doses of psychedelic substances to theoretically support focus,
executive control, and goal-directed behavior, which may result in
secondary improvements in emotional regulation and psychiatric wellbeingwould
fall into this category. The bulk of microdosing research appears
to be inconclusive and/or poorly blinded. The minimum level of cortical
or subcortical activation required to elicit growth without perceptual
effects has yet to be tested directly.

Finally, a circuit-level view is necessary for assessing the true
therapeutic potential of these compounds. While the 5-HT2A receptor appears important, all psychedelics and nonpsychoactive
analogues studied today engage a plethora of targets. The summation of receptor activation and what downstream
circuits may be indirectly activated for therapeutic and/or perceptual
effects requires further study.

While nonpsychoactive analogues hold promise for bringing a more
accessible medication to the public, it is possible that hallucinations
provide a more robust or more long-lasting therapeutic effect.

Animal Models

Animal models are a critical component
of drug discovery and development. Such models offer advantages for
defining psychedelics’ mechanism of action, neurobiological
mechanisms such as neuroplasticity, duration of action, and biomarkers.
These models may help to unlock the capacity to develop the next generation
of psychedelics. There are notable advantages of animal models, such
as rigorous control of experimental variables, the capacity to perform
deep mechanistic studies, the capacity to use sophisticated genetic
and neural circuitry techniques, the capacity to perform longitudinal
studies throughout the lifespan of the organism, and the capacity
to validate and extend cellular findings and mechanisms. For example,
it is well established that the history of the organism (including
behavioral and drug history) and the current environment in which
a drug is administered can influence the effects of the administered
drug., This is certainly true for the psychedelics,
and has been referred to as “set and setting.”,, Laboratory animals provide exquisite
control over the history of the organism and its current environment.
In combination with rigorous techniques from the experimental analysis
of behavior, this can provide important insights into the in vivo
pharmacology of psychedelics.

Animal models can be used to define
the fundamental pharmacology of psilocybin. This is an excellent pairing
with in vitro and cellular assays. Concordance between cellular and
laboratory animal pharmacology end points supports the rationale that
findings will generalize to humans, including in clinical settings.
It is also important to note that several influential ideas in the
psychedelic field, such as biased agonism and intracellular receptor
signaling that especially relate to the development of next-generation
psychedelics, have garnered disproportionate support from cellular
assays that could be susceptible to artificial cellular conditions
that may not occur in whole organisms. Additional support from in
vivo pharmacology experiments would strengthen the case that such
ideas will have therapeutic relevance.

Historically, the bulk of animal research with psychedelics has
involved studying their fundamental in vivo and behavioral pharmacology,
especially to delineate the receptors that mediate specific behavioral
responses, shared effects between different psychedelics and among
different classes of psychedelics, and to define pharmacological changes
such as tolerance. Almost no research has focused on therapeutic applications.
This is because many of the animal studies with psychedelics that
occurred between the 1970s and early 2000s focused on their misuse
liability. During that period, scientifically, the psychedelic effect
itself was considered to be a marker of misuse liability. More practically,
during that time, the limited available funding for research with
psychedelics was issued for the study of their harm. Despite these
constraints, research from the Nichols, Glennon, Sanders-Bush, Winter,
Cunningham, Howell, and Fantegrossi laboratories, among others, did
pioneering research into the behavioral pharmacology and neuropharmacology
of psychedelics. With the renaissance of psychedelic research that
has occurred in the past 15 years or so, and especially the profound
therapeutic responses that have been reported in clinical research,
there is a new impetus to generate animal models that would capture
and allow for a deep mechanistic understanding of the therapeutic
response to psychedelics.

There are three major categories of behavioral pharmacology techniques
that are commonly applied across different classes of psychoactive
drugs: assays of the directly elicited effects of drugs, assays of
their interoceptive/subjective effects, and assays of their hedonic,
reinforcing, or motivational effects. This largely parallels the assays
that can be used in defining the misuse liability and addictive potential
of substances in humans. Studying directly elicited effects can be
used to study the in vivo pharmacology of psychoactive drugs by the measurement of an unconditioned behavior
following drug administration. Such procedures have been applied to
stimulants using locomotor activity, opioids with the Straub tail
response, and cannabinoids with the tetrad procedure. In the context
of psychedelics, the unconditioned behavior that has been most commonly
studied is the head-twitch response (HTR)., The HTR is commonly used to study effects of psychedelics in rodents
and presents as rapid, rotational jerks of the head or high-frequency
paroxysmal head rotation. Head twitching
occurs in rodents spontaneously but, importantly, is selectively increased
in frequency by psychedelics.−

The number of head twitches in a given period of time is correlated
to psychedelic potency in humans. This
assay has been widely used by behavioral pharmacologists for decades
and has provided critical data demonstrating that serotonin 5-HT2A receptors are a critical molecular mediator of this elicited
response, as the HTR is blocked by the selective antagonist M100907, or genetic ablation of the 5-HT2A receptor.−

Likewise, it has been suggested that findings from this assay can
shed light on the mechanisms underlying the psychoactive effects of
psychedelics. This idea rests primarily on the correlations of potency
antagonist blockade of the HTR with affinity for 5-HT2A receptors,, affinity at 5-HT2 receptors, and psychedelic potency in humans. Furthermore, this assay may have utility in the development
of the next generation of psychedelics, as there is interest in the
idea that compounds that lack psychedelic activity can maintain the
therapeutic response. As such, a positive response in a therapeutic
assay concurrent with a negative response in the HTR assay would possibly
indicate a compound with the potential to treat addiction, depression,
anxiety, or other disease in the absence of psychedelic activity.
Finally, this assay continues to have utility in defining fundamental
behavioral, pharmacological, and neuropharmacological mechanisms.
The HTR appears to have the capacity to discriminate psychedelic from
nonpsychoactive drugs that both act as agonists of 5-HT2A receptors.

While the HTR has provided enormous utility in psychedelic research,
especially in their behavioral pharmacology and receptor mechanisms,
it is important to consider the nuances of this assay and that, like
any assay, it has limitations on its application and interpretation.
For one, it is important to note that there are many other unconditioned
effects elicited by psychedelics and that the presentation of such
elicited responses can vary among species. Psychedelics can also elicit
changes in social behavior, induce convulsions and seizures at higher
doses, and exhibit other elicited effects
if they have polypharmacological activity at a diversity of serotonin
receptors, particularly the 5-HT1A and 5-HT2C receptors. The HTR is typically measured in mice but has a more
whole-body presentation in rats, where it is described as wet dog
shakes. Nonhuman primates do not exhibit
either response but rather exhibit a psychedelic-elicited fly-catching
behavior. Similarly, there is no established human counterpart to
the HTR. Second, there are several notable false positives with this
assay, in that there are 5-HT agonists that produce HTR but do not
produce psychedelic subjective effects in humans., Third, the HTR does not seem to be a particular quantitative measure
of psychedelic activity in that there are strong psychedelics that
produce a weaker HTR (notably the tryptamine analogues) and strong
psychedelics that produce a more robust HTR (notably the phenethylamine
analogues). As such, there may be a threshold level, rather than a
linear level, of the HTR that defines a psychedelic response, but
this remains to be determined. Finally, it is possible that the HTR
involves elements of spinal reflexes rather than brain-mediated responses,
which could have great meaning when species differences in the 5-HT2A
receptor and its distribution are considered. Nonetheless, HTR remains
a widely used assay of target engagement of 5-HT2A receptors in whole
organisms, in part because this unconditioned behavior can be assessed
without any training or other extensive procedures, as is the case,
for example, with drug discrimination.

An alternative to the HTR is drug discrimination assays. For several
decades, these were mainstays in the study of psychedelics but for
the past decade or so have fallen out of favor. Drug discrimination
is a complex learning task in which an animal learns to press one
lever when it receives the training drug and another lever when it
receives a vehicle. Responding on the correct lever produces the presentation
of a food reinforcer such as a sucrose pellet. The animal is trained
to discriminate the interoceptive effects of a psychedelic, typically
in comparison to vehicle, by associating these interoceptive effects
with responding on the drug-paired lever., Specifically, on sessions when the animal has received pretreatment
with a specific drug, a particular response in the chamber (e.g.,
left lever presses) is reinforced (e.g., with food). On other days
when the animal has received vehicle pretreatment, another particular
response (e.g., right lever presses) is reinforced. After a number
of training sessions, the animal can discriminate the test drug with
high reliability (e.g., with ≥ 90% accuracy). While there is
complexity to this, these interoceptive effects are often thought
to be analogous to the subjective effects produced in humans, such
as psychedelic activity.

However, human research using drug discrimination has suggested
that drug discrimination and subjective effects are not identical
but rather provide complementary results. Upon successful training, the animal can be exposed to test drugs
to determine if they produce interoceptive effects that are similar
in potency and/or efficacy to those of the training drug. This is
a powerful assay in that it allows the experimenter to establish key
aspects of the subjective and psychoactive effects of psychedelics,
including their relationship to therapeutic responses and underlying
mechanisms. As there has been great debate in the clinical literature
regarding the role of subjective effects in therapeutic response,
this assay could be pivotal in the development of the next generation
of psychedelics. In addition, drug discrimination also provides a
measure of the rate of response, which can be used as an internal
control to rigorously verify that a physiologically and pharmacologically
relevant dose range is being tested. Drug discrimination can also
provide information on the onset and duration of action of the subjective
experience of a psychedelic, something with profound implications
for the access and scalability of next-generation psychedelics. As such, drug discrimination provides notable
advantages over the HTR in the specific modeling of the interoceptive/subjective
effects of psychedelics. This assay
allows the experimenter to recapitulate drug responses (e.g., potency
and efficacy) and doses that are characteristic of the psychedelic
response in humans. Given the low throughput of this assay, it has
yet to be extensively used to test novel nonpsychoactive analogues
of psychedelic compounds. We encourage authors entering this field
to use this assay or variants when possible.

Drug self-administration is the gold standard for studying the
reinforcing and addictive effects of hedonic drugs (like opioids).
Self-administration specifically examines the extent to which a drug
of misuse serves as an operant reinforcer. This can be done with a
design in which an operant response such as a lever press or a nose
poke occasions an injection of drug through a diversity of routes
of administration, including intravenous, oral, inhaled, or other
routes. The most common route is intravenous administration, as this
facilitates the capacity of the animal to learn the association between
the response and the initiation of the drug effect. Drug self-administration
assays can result in multiple meaningful metrics of drug reinforcement,
including overall drug consumption, response rate, breakpoint, or
several behavioral economic measures, including demand intensity and
demand elasticity for the drug.,

Self-administration models can also be embedded in reinstatement
experimental methods, which test the ability of a drug-associated
cue or context to once again prompt drug self-administration behavior
after a period in which self-administration of the drug has been extinguished. During much of the 20th and early 21st centuries,
the use of self-administration procedures with psychedelics was focused
on establishing their potential misuse liability and addiction potential.
The consistent finding from this research is that animals will not
readily self-administer psychedelics.,,,, This lies in stark contrast to nearly every other class of misused
or addictive substances, including alcohol, stimulants, sedatives,
nicotine, and cannabinoids, all of which show robust self-administration
under appropriate conditions. Indeed, part of the reason that self-administration
is considered a gold standard assay is the finding of a nearly perfect
alignment between which substances are misused by humans and self-administered
by animals, with the notable and sole exception of psychedelics.

Generally, reinforcing properties of drugs are thought to be mediated
by dopamine (DA) increases in key areas of the brain such as the nucleus
accumbens (NA) and ventral tegmental area (VTA). All strongly reinforcing
drugs increase dopamine levels in the NA directly or indirectly. In
contrast, there is very little evidence that psychedelics can produce
such effects. There have been several preliminary efforts to create
procedures that allow for psychedelic self-administration, using agents
such as LSD, DMT, psilocybin, mescaline, and DOI, all of which have
failed to produce even one consistently self-administering animal.,,−

In one study, a single rhesus monkey did reliably self-administer
DMT, but only after 6 days of complete sensory deprivation. It is well established that a drug history
in animals trained to self-administer drugs is a critical determinant
in whether and to what extent these animals will self-administer different
drugs. This is especially the case for self-administration of a drug
by an animal experienced with or maintained on a drug with similar
interoceptive effects., Even under conditions
when drugs are substituted for maintenance drugs with similar discriminative
stimulus/interoceptive properties such as MDMA, it is difficult to document self-administration reliably.
However, even though self-administration is not maintained for any
extended period of time, there were several experimental sessions
that occurred with no apparent pattern in which monkeys would earn
most or all of the available injections of DMT, psilocybin, or mescaline
when substituted for MDMA at rates of responding several times that
of the saline control, which is consistent with use patterns in humans.

Following the renaissance in psychedelic research and the new impetus
to study their therapeutic properties, increased examination of psychedelic
compounds in their potential to change the self-administration of
addictive drugs would significantly propel the area of psychedelics
for substance use disorders. Very few studies have been published
in this regard. Only recently, two groups published that the psychedelic
DOI attenuates the reinforcing effects of alcohol., To our knowledge, these were the very first studies to report that
a psychedelic can attenuate the self-administration of any misused
drug.

As mentioned, there is now a new impetus to research on the therapeutic
mechanisms of psychedelics. There are several caveats in this regard.
For one, it is not yet settled whether the therapeutic response to
psychedelics relies on the induction of a mystical experience. If
such experiences turn out to be necessary, it is unclear whether there
is any animal analog to such an effect or, if it occurs, how it can
be observed, quantified, and measured by an experimenter. One of the
effects of psychedelics in humans is ineffability, meaning that the
experience surpasses the capacity of language to express it. One of
the long-standing limitations of animal models is the need to measure
and interpret effects in a nonverbal species. This may be even more
challenging, given that even a verbal species has difficulty conveying
what occurred. Second, the clinically measured therapeutic responses
to psychedelics are remarkable in a number of ways, including that
under optimized, prepared, and supportive conditions, they occur in a large portion of participants, they are
very strong effects, they occur seemingly instantly, they occur in
individuals with long-standing and intractable illnesses, and they
are persistent following a single administration. Some of these findings
will make it easier to study the underlying mechanisms in animals,
including that these are robust effects that emerge quickly. Some
will make it more challenging, such as their persistence and that
they may emerge following long illness histories. Third, it is believed
that the “set and setting” strongly influence the therapeutic
responses, including elements of preparation and supportive psychotherapy.

This may be very challenging to translate into animals, though
attempts have been made. To date, no
published studies have reported attempts to use procedures such as
‘preparation’ in animal models. Likewise, it is unclear
whether setting elements such as specific music or lighting conditions
would attenuate or augment the therapeutic response in animals. Overcoming
some of these challenges will require exciting and rigorous research,
and success would greatly aid in the development of the next generation
of psychedelic drug development.

As with behavioral pharmacology, there are many well-validated
procedures that have been used for decades in the field of behavioral
neuroscience. The forced swim test (FST) and tail suspension test
(TST) are quick tests that are used to test certain behaviors in mice
and rats.−

For the FST, animals are placed in a tank
of room temperature to lukewarm water such that they can not touch
the bottom with either their paws or tails and are observed for 5–6
min. During this time, the animal will either move about (e.g., swimming,
climbing; motivated behaviors) or float immobile (‘give up’,
behavioral despair). Various forms of stressors have been shown to
lead to increased immobility, and presumably behavioral despair, and
treatment with certain antidepressants like SSRIs can reverse this
stress-induced immobility. Similarly, the TST suspends a mouse up
by its tail for 6 min, and the amount of time the animal spends moving
and trying to escape during the last 4 min is quantified as motivated
behavior. Certain stress paradigms result in more immobility and simple
hanging in this assay. These tests have good predictive validity for
identifying drugs with antidepressant efficacy in humans. Several
research groups have demonstrated that both psychedelics and nonpsychoactive
analogs of psychedelics are efficacious at restoring motivated behaviors
in these paradigms in both mice and rats.,,,, There are unfortunately two inherent problems with
FST, one of which is shared with TST. For both FST and TST, drug dosing
is typically subchronic, with dosing 24, 5, and 1 h prior to testing
to cause reversal of the “depressed” phenotypic response. However, these agents (e.g., SSRIs, tricyclic
antidepressants) show a delayed (up to 2 months) therapeutic onset
in humans. This is in contrast to psychedelics, which can produce
a rapid reversal of the “depressed” phenotype that can
last for months after a single administration. Additionally, in the
FST, rodents can learn that if they float without having to struggle
(passive coping mechanism), they will be rescued, so repeated use
of FST in an individual animal may test learning as much as “depression”.

The Sucrose Preference Test (SPT) is used as a measure of anhedonia
in rodents. When an animal is presented
with two bottles (one with regular water, and the other sweetened
with sucrose), the animal will prefer sucrose water. After chronic
stress and/or induction of a depressive phenotype, the animal loses
its preference for the rewarding bottle. This is seen as anhedonic
response. As with FST and TST, this can be reversed with an antidepressant
treatment. Multiple groups have demonstrated that after chronic stress,
sucrose preference declines and psilocybin rescues this phenotype.,

Learned helplessness has excellent face value and predictive value. Briefly, an animal is subjected to an inescapable
stressor (e.g electric shocks), which induces a depressive-like state
such that, when given an exit strategy, animals “endure”
the stressor rather than trying to escape (learned helplessness).
“Giving up” is a common symptom in patients with depression.
The Kwan lab has demonstrated that psilocybin has the potential to
reverse this behavior and restore motivated behaviors.,

Another test that has been used to assess the behavioral effects
of psilocybin is object-pattern separation. This is a cognitive behavior dependent on a specific hippocampal
circuit shared between rodents and humans and therefore has high translational
value. Chronic stress in rats eliminates the ability of the animals
to detect pattern changes in their environment, and a single treatment
with psilocybin appears to reverse the effects of stress long-term
and restore the ability to recognize pattern changes.

Biomarkers

Great progress has been made in establishing
possible benefits from psychedelic therapy for mood disorders, but
there is still much to be done. Progress depends on several factors
that currently influence successful or useful outcomes for both basic
and clinical research.

There are two related issues that are
not unique to psychedelics, but are certainly vexing to their development
as potential therapeutics. One concerns current “quantification”
of the symptoms of mood and anxiety disorders and the quantification
of the extent to which they contribute to the degree of disability
in a given subject. For the issue of disease/disability quantification,
there is no shortage of rating scales that create a profile of disease
within a given subject (depression and anxiety are most often comorbid)
and assign a numerical value. Some of these tests are self-administered
and others are administered by a professional (not necessarily one
with extensive mental health experience). All of these scales are
“fuzzy” and dependent on the current mindset of the
rater (whether self-administered or not). Another notable exception
for these concerns is substance use disorders, where biological confirmation
of drug use status at study intake and drug use or abstinence after
treatment substantially addresses those concerns. One example is research
using psilocybin to treat tobacco use disorder, in which exhaled carbon
monoxide and urinary cotinine are used as methods for bioverification
of tobacco use vs abstinence. Another
example has been research using psilocybin to treat alcohol use disorder,
where hair or fingernail samples have been analyzed for ethylglucuronide
concentration as bioverification of abstinence self-report in a subset
of participants. However, there are no
such biomarkers for psychiatric disorders outside of substance use.
Thus, it is imperative to establish biological hallmarks (biomarkers)
that can be used to both confirm and quantify diagnosis. As of this
writing, this has proven elusive. A profound limitation of current
research is the lack of biomarkers for psychedelic therapeutic activity
in early drug development. This is important because many of the limitations
of first-generation compounds listed above relate to properties (such
as the nature of subjective experience) that are indirectly tied to
therapeutics and which are lacking biomarkers.

One significant problem for biological hallmarks of disease is
that at least in the case of major depressive disorder, what is described
as a single entity may have a number of root causes that manifest
as a constellation of symptoms. Genomics have not proven particularly
useful for understanding depression, and some of the genes thought
to cause depression-like behaviors in mice have not been observed
to be relevant for depression in humans. Two published studies examined major depressive disorder proteomesdeduced
from genome/gene expression and mRNA
for prediction of mood state and treatment response. There was no overlap in targets between these studies,
illustrating the difficulty of genetic/genomic accounting in the assignment
of a biomarker.

Imagingincluding EEG, fMRI, and DTIhas been used
to indicate both depression and likely treatment response,−

and there are recent suggestions that structural brain imaging might
predict treatment response for depression. However, it is important to recognize that “prediction”
in such studies will refer to the observation of group differences
based on disorder or prepost analysis. Advances will be needed in
order to have greater predictability at the individual level for either
diagnosis or clinical prediction of treatment response. Analysis of
digital data obtained from cellphone keyboards (keystrokes, mistakes)
may also prove as a biomarker for mood.

One consistent hallmark of depression, in both human and animal
models, has been attenuation of cAMP signaling, which is restored
upon successful antidepressant response. This has been observed in
11C Rolipram PET imaging studies, where brain cAMP was lower during
depression and returned to baseline in those subjects showing positive
clinical response to antidepressant therapy. Recently, this has been translated into a simple platelet biomarker,
wherein augmentation of the activation of the cAMP-generating enzyme,
adenylyl cyclase, by the G protein (Gsα), reveals the presence
of depression and tracks with positive antidepressant responses., It is hoped that these biomarkers, and those yet to be developed,
show a continuity for depression diagnostics as well as a confluence
of response to antidepressant agents, including psychedelics. A clear
demonstration of common diagnostic and predictive pathways will certainly
help to establish clinical validity and utility for psychedelic compounds.

Critical Assays, Summary of Strengths/Weaknesses of the Field,
Pathways Forward

The field of psychedelic science has expanded
rapidly in recent decades and made enormous progress for treating
neuropsychiatric disorders. While preliminary research with first-generation
psychedelics is very promising, there are several limitations of these
compounds and treatments that may limit their clinical dissemination.
The surge of novel psychedelics and psychedelic analogues provides
hope for improving patient care and expanding dissemination while
minimizing side effects. Current animal behavioral studies are beneficial,
though further refinement of assays like HTR and FST and the development
of novel tests with greater sensitivity and reliability would help
to push the field forward in screening novel compounds. Finally, biomarkers
in humans may help to diagnose and guide the therapeutic treatment
for patients.

Our work has summarized the efforts in psychedelic
drug discovery, the hurdles, the triumphs, and possibilities. We hope
that this serves to ground us as we push the boundaries of the field
forward. Hopefully, the next few years will show great progress toward
providing novel therapeutics for those who suffer.

Goodwin G. M. Aaronson S. T. Alvarez O. Single-dose psilocybin
for a treatment-resistant episode of major depression: Impact on patient-reported
depression severity, anxiety, function, and quality of life J. Affective Disord. 2023 327 120 127 10.1016/j.jad.2023.01.108 36740140

Raison C. L. Sanacora G. Woolley J. Single-Dose Psilocybin
Treatment for Major Depressive Disorder: A Randomized Clinical Trial JAMA 2023 330 843 853 10.1001/jama.2023.14530 PMC10472268 37651119

Agrawal M. Richards W. Beaussant Y. Psilocybin-assisted
group therapy in patients with cancer diagnosed with a major depressive
disorder Cancer 2024 130 1137 1146 10.1002/cncr.35010 38105655

Ross S. Bossis A. Guss J. Rapid and sustained
symptom reduction following psilocybin treatment for anxiety and depression
in patients with life-threatening cancer: a randomized controlled
trial J. Psychopharmacol. 2016 30 1165 1180 10.1177/0269881116675512 PMC5367551 27909164

Bogenschutz M. P. Ross S. Bhatt S. Percentage of Heavy
Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo
in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized
Clinical Trial JAMA Psychiatry 2022 79 953 962 10.1001/jamapsychiatry.2022.2096 PMC9403854 36001306

Johnson M. W. Garcia-Romeu A. Cosimano M. P. Griffiths R. R. Pilot study
of the 5-HT2AR agonist psilocybin in the treatment of tobacco addiction J. Psychopharmacol. 2014 28 983 992 10.1177/0269881114548296 PMC4286320 25213996

Aaronson S. T. van der Vaart A. Miller T. Single-Dose Synthetic
Psilocybin With Psychotherapy for Treatment-Resistant Bipolar Type
II Major Depressive Episodes: A Nonrandomized Controlled Trial JAMA Psychiatry 2023 81 555 562 10.1001/jamapsychiatry.2023.4685 PMC10701666 38055270

Halberstadt A. L. Koedood L. Powell S. B. Geyer M. A. Differential contributions
of serotonin receptors to the behavioral effects of indoleamine hallucinogens
in mice J. Psychopharmacol. 2011 25 1548 1561 10.1177/0269881110388326 PMC3531560 21148021

Schindler E. A. D. The
Potential of Psychedelics for the Treatment of Episodic Migraine Curr. Pain Headache Rep. 2023 27 489 495 10.1007/s11916-023-01145-y 37540398

Mitchell J. M. Ot’alora G M. van der Kolk B. MDMA-assisted therapy
for moderate to severe PTSD: a randomized, placebo-controlled phase
3 trial Nat. Med. 2023 29 2473 2480 10.1038/s41591-023-02565-4 PMC10579091 37709999

Marseille E. Mitchell J. M. Kahn J. G. Updated cost-effectiveness of MDMA-assisted
therapy for the treatment of posttraumatic stress disorder in the
United States: Findings from a phase 3 trial PLoS One 2022 17 e026325210.1371/journal.pone.0263252 PMC8880875 35213554

Johnson M. W. Hendricks P. S. Barrett F. S. Griffiths R. R. Classic
psychedelics: An integrative review of epidemiology, therapeutics,
mystical experience, and brain network function Pharmacol. Ther. 2019 197 83 102 10.1016/j.pharmthera.2018.11.010 30521880

Strickland J. C. Garcia-Romeu A. Johnson M. W. The Mystical Experience Questionnaire
4-Item and Challenging Experience Questionnaire 7-Item Psychedelic Med. 2024 2 33 43 10.1089/psymed.2023.0046 PMC11658653 40051759

Liechti M. E. Dolder P. C. Schmid Y. Alterations of consciousness and
mystical-type experiences after acute LSD in humans Psychopharmacology 2017 234 1499 1510 10.1007/s00213-016-4453-0 PMC5420386 27714429

Nayak S. M. Bradley M. K. Kleykamp B. A. Control Conditions in
Randomized Trials of Psychedelics: An ACTTION Systematic Review J. Clin. Psychiatry 2023 84 22r1451810.4088/jcp.22r14518 37167563

Olson D. E. The Subjective
Effects of Psychedelics May Not Be Necessary for Their Enduring Therapeutic
Effects ACS Pharmacol. Transl. Sci. 2021 4 563 567 10.1021/acsptsci.0c00192 PMC8033607 33861218

Jones K. A. Srivastava D. P. Allen J. A. Rapid modulation of
spine morphology by the 5-HT2A serotonin receptor through kalirin-7
signaling Proc. Natl. Acad. Sci. U.S.A. 2009 106 19575 19580 10.1073/pnas.0905884106 PMC2780750 19889983

Shao L.-X. Liao C. Gregg I. Psilocybin induces rapid
and persistent growth of dendritic spines in frontal cortex in vivo Neuron 2021 109 2535 2544 10.1016/j.neuron.2021.06.008 PMC8376772 34228959

Ly C. Greb A. C. Cameron L. P. Psychedelics Promote
Structural and Functional Neural Plasticity Cell Rep. 2018 23 3170 3182 10.1016/j.celrep.2018.05.022 PMC6082376 29898390

Cameron L. P. Benson C. J. Dunlap L. E. Olson D. E. Effects of N,N-Dimethyltryptamine
on Rat Behaviors Relevant to Anxiety and Depression ACS Chem. Neurosci. 2018 9 1582 1590 10.1021/acschemneuro.8b00134 PMC7196340 29664276

Vargas M. V. Dunlap L. E. Dong C. Psychedelics promote
neuroplasticity through the activation of intracellular 5-HT2A receptors Science 2023 379 700 706 10.1126/science.adf0435 PMC10108900 36795823

Hertenstein E. Trinca E. Schneider C. L. Augmentation of Psychotherapy
with Neurobiological Methods: Current State and Future Directions Neuropsychobiology 2021 80 437 453 10.1159/000514564 33910218

Salfiti M. Kyriazis M. Mikellides G. Zalsupindole: A Non-Hallucinogenic
Psychoplastogen Advancing Psychedelic-Inspired Therapeutics ACS Chem. Neurosci. 2026 17 382 391 10.1021/acschemneuro.5c00707 41493772

Chwelos N. Blewett D. B. Smith C. M. Hoffer A. Use of d-lysergic acid
diethylamide in the treatment of alcoholism Q. J. Stud. Alcohol 1959 20 577 590 10.15288/qjsa.1959.20.577 13810249

Anderson B. T. Danforth A. Daroff P. R. Psilocybin-assisted
group therapy for demoralized older long-term AIDS survivor men: An
open-label safety and feasibility pilot study EClinicalMedicine 2020 27 10053810.1016/j.eclinm.2020.100538 PMC7599297 33150319

Noorani T. Garcia-Romeu A. Swift T. C. Griffiths R. R. Johnson M. W. Psychedelic therapy for smoking cessation: Qualitative
analysis of participant accounts J. Psychopharmacol. 2018 32 756 769 10.1177/0269881118780612 29938565

Robison R. Barrow R. Conant C. Single treatment with
MM120 (lysergide) in generalized anxiety disorder: A randomized clinical
trial JAMA 2025 334 1358 1372 10.1001/jama.2025.13481 PMC12412041 40906494

Cubala W. J. Bajbouj M. Bauer M. GH001 vs Placebo in
Patients With Treatment-Resistant Depression: A Randomized Clinical
Trial JAMA Psychiatry 2026 83 561 569 10.1001/jamapsychiatry.2026.0096 PMC13019340 41879760

Shulgin , A. TIHKAL: Tryptamines I
Have Known and Loved ; Transform Press: Berkeley, 1997 ; pp 412 –415 .

Ermakova A. O. Dunbar F. Rucker J. Johnson M. W. A narrative synthesis
of research with 5-MeO-DMT J. Psychopharmacol. 2022 36 273 294 10.1177/02698811211050543 PMC8902691 34666554

Dourron H. M. Nichols C. D. Simonsson O. 5-MeO-DMT: An atypical
psychedelic with unique pharmacology, phenomenology & risk? Psychopharmacology 2023 242 1457 1479 10.1007/s00213-023-06517-1 38072874

Nutt , D. J. ; Peill , J. M. ; Weiss , B. Psilocybin
and Other Classic Psychedelics in Depression . In Current Topics in Behavioral Neurosciences ; Springer Nature, 2023 10.1007/7854_2023_451 .37955822

Breeksema J. J. Kuin B. W. Kamphuis J. Adverse events in clinical
treatments with serotonergic psychedelics and MDMA: A mixed-methods
systematic review J. Psychopharmacol. 2022 36 1100 1117 10.1177/02698811221116926 PMC9548934 36017784

Carbonaro T. M. Bradstreet M. P. Barrett F. S. Survey study of challenging
experiences after ingesting psilocybin mushrooms: Acute and enduring
positive and negative consequences J. Psychopharmacol. 2016 30 1268 1278 10.1177/0269881116662634 PMC5551678 27578767

Studerus E. Gamma A. Vollenweider F. X. Psychometric evaluation of the altered
states of consciousness rating scale (OAV) PLoS One 2010 5 e1241210.1371/journal.pone.0012412 PMC2930851 20824211

Straumann I. Ley L. Holze F. Acute effects of MDMA and LSD co-administration
in a double-blind placebo-controlled study in healthy participants Neuropsychopharmacology 2023 48 1840 1848 10.1038/s41386-023-01609-0 PMC10584820 37258715

Lyvers M. Meester M. Illicit use of LSD or psilocybin, but not MDMA or nonpsychedelic
drugs, is associated with mystical experiences in a dose-dependent
manner J. Psychoact. Drugs 2012 44 410 417 10.1080/02791072.2012.736842 23457892

Schmid Y. Gasser P. Oehen P. Liechti M. E. Acute subjective
effects in LSD- and MDMA-assisted psychotherapy J. Psychopharmacol. 2021 35 362 374 10.1177/0269881120959604 33853422

Zeifman R. J. Kettner H. Pagni B. A. Co-use of MDMA with
psilocybin/LSD may buffer against challenging experiences and enhance
positive experiences Sci. Rep. 2023 13 1364510.1038/s41598-023-40856-5 PMC10444769 37608057

Johnson M. Richards W. Griffiths R. Human hallucinogen research: guidelines
for safety J. Psychopharmacol. 2008 22 603 620 10.1177/0269881108093587 PMC3056407 18593734

Hutcheson J. D. Setola V. Roth B. L. Merryman W. D. Serotonin receptors
and heart valve disease--it was meant 2B Pharmacol.
Ther. 2011 132 146 157 10.1016/j.pharmthera.2011.03.008 PMC3179857 21440001

Malcolm B. Thomas K. Serotonin toxicity of serotonergic psychedelics Psychopharmacology 2022 239 1881 1891 10.1007/s00213-021-05876-x 34251464

Luz M. Mash D. C. Evaluating the toxicity and therapeutic potential of
ibogaine in the treatment of chronic opioid abuse Expert Opin. Drug Metab. Toxicol. 2021 17 1019 1022 10.1080/17425255.2021.1944099 34139922

Cherian K. N. Keynan J. N. Anker L. Magnesium-ibogaine therapy
in veterans with traumatic brain injuries Nat.
Med. 2024 30 373 381 10.1038/s41591-023-02705-w PMC10878970 38182784

Jain M. K. Gumpper R. H. Slocum S. T. The polypharmacology
of psychedelics reveals multiple targets for potential therapeutics Neuron 2025 113 3129 3142 10.1016/j.neuron.2025.06.012 PMC13632693 40683247

Shulgin , A. ; Shulgin , A. PIHKAL: A Chemical
Love Story . 1991 .

Nichols D. E. Structure-activity
relationships of serotonin 5-HT2A agonists Wiley Interdiscip. Rev.: Membr. Transp. Signaling 2012 1 559 579 10.1002/wmts.42

Nichols D. E. Psychedelics Pharmacol. Rev. 2016 68 264 355 10.1124/pr.115.011478 PMC4813425 26841800

Nichols D. E. Chemistry
and Structure-Activity Relationships of Psychedelics Curr. Top. Behav. Neurosci. 2018 36 1 43 10.1007/7854_2017_475 28401524

Nichols D. E. Shulgin A. T. Sulfur analogs of psychotomimetic amines J. Pharm. Sci. 1976 65 1554 1556 10.1002/jps.2600651040 978423

Glennon R. A. The 2014
Philip S. Portoghese Medicinal Chemistry Lectureship: The “Phenylalkylaminome”
with a Focus on Selected Drugs of Abuse J.
Med. Chem. 2017 60 2605 2628 10.1021/acs.jmedchem.7b00085 PMC5824997 28244748

Glennon R. A. Titeler M. McKenney J. D. Evidence for 5-HT2 involvement in
the mechanism of action of hallucinogenic agents Life Sci. 1984 35 2505 2511 10.1016/0024-3205(84)90436-3 6513725

Aday J. S. Barnett B. S. Grossman D. Psychedelic Commercialization:
A Wide-Spanning Overview of the Emerging Psychedelic Industry Psychedelic Med. 2023 1 150 165 10.1089/psymed.2023.0013 PMC11661494 40046566

McFadden v.. Justia
Law United States 2015 https://supreme.justia.com/cases/federal/us/576/186/186.

Paul S. M. Mytelka D. S. Dunwiddie C. T. How to improve R&D
productivity: the pharmaceutical industry’s grand challenge Nat. Rev. Drug Discovery 2010 9 203 214 10.1038/nrd3078 20168317

AbbVie to Acquire Gilgamesh Pharmaceuticals’ Bretisilocin,
a Novel, Investigational Therapy for Major Depressive Disorder, Expanding
Psychiatry Pipeline 2025 https://news.abbvie.com/2025-08-25-AbbVie-to-Acquire-Gilgamesh-Pharmaceuticals-Bretisilocin,-a-Novel,-Investigational-Therapy-for-Major-Depressive-Disorder,-Expanding-Psychiatry-Pipeline.

Otsuka Pharmaceutical Co., Ltd.. Otsuka Pharmaceutical to Acquire Transcend Therapeutics - Expands
Otsuka portfolio in psychiatric and neurological fields and aims to
accelerate development of Transcend’s portfolio, including
the TSND-201 program for post-traumatic stress disorder (PTSD) 2026 https://www.otsuka.co.jp/en/company/newsreleases/2026/20260327_2.html.

Eli Lilly and Company. Lilly to acquire AtaiBeckley to advance therapies for treatment-resistant
depression and other mental health conditions . https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-ataibeckley-advance-therapies-treatment-resistant.

Kaplan A. L. Confair D. N. Kim K. Bespoke library docking
for 5-HT2A receptor agonists with antidepressant activity Nature 2022 610 582 591 10.1038/s41586-022-05258-z PMC9996387 36171289

Cameron L. P. Tombari R. J. Lu J. A non-hallucinogenic
psychedelic analogue with therapeutic potential Nature 2021 589 474 479 10.1038/s41586-020-3008-z PMC7874389 33299186

Dunlap L. E. Azinfar A. Ly C. Identification of Psychoplastogenic
N, N-Dimethylaminoisotryptamine (isoDMT) Analogues through Structure-Activity
Relationship Studies J. Med. Chem. 2020 63 1142 1155 10.1021/acs.jmedchem.9b01404 PMC7075704 31977208

Ludbrook G. Bryson N. Taylor B. Safety, Tolerability,
Pharmacokinetics, and Pharmacodynamics of Subcutaneous RE104: A Double-Blind,
Randomized, Single Ascending Dose Placebo-Controlled Study J. Clin. Psychopharmacol. 2025 45 441 453 10.1097/JCP.0000000000002047 PMC12379775 40685873

Cybin Reports Positive Topline Data from Phase 2 Study of CYB003
in Major Depressive Disorder with 79% of Patients in Remission after
Two 12mg Doses . https://ir.helus.com/news-releases/news-release-details/cybin-reports-positive-topline-data-phase-2-study-cyb003-major.

AtaiBeckley Inc.. atai Life Sciences Announces Update on Beckley Psytech’s Phase
1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder,
with Initial Results from Phase 1 and First Patients Dosed in Phase
2a . https://ir.ataibeckley.com/news-releases/news-release-details/atai-life-sciences-announces-update-beckley-psytechs-phase-12a/.

Wallach J. Cao A. B. Calkins M. M. Identification of 5-HT2A
receptor signaling pathways associated with psychedelic potential Nat. Commun. 2023 14 822110.1038/s41467-023-44016-1 PMC10724237 38102107

Lewis V. Bonniwell E. M. Lanham J. K. A non-hallucinogenic
LSD analog with therapeutic potential for mood disorders Cell Rep. 2023 42 11220310.1016/j.celrep.2023.112203 PMC10112881 36884348

Vollenweider F. X. Vollenweider-Scherpenhuyzen M. F. I. Bäbler A. Vogel H. Hell D. Psilocybin induces schizophrenia-like
psychosis in humans via a serotonin-2 agonist action NeuroReport 1998 9 3897 3902 10.1097/00001756-199812010-00024 9875725

Kraehenmann R. Pokorny D. Vollenweider L. Dreamlike effects of
LSD on waking imagery in humans depend on serotonin 2A receptor activation Psychopharmacology 2017 234 2031 2046 10.1007/s00213-017-4610-0 28386699

Kometer M. Schmidt A. Jäncke L. Vollenweider F. X. Activation
of serotonin 2A receptors underlies the psilocybin-induced effects
on α oscillations, N170 visual-evoked potentials, and visual
hallucinations J. Neurosci. 2013 33 10544 10551 10.1523/JNEUROSCI.3007-12.2013 PMC6618596 23785166

Kim K. Che T. Panova O. Structure of a Hallucinogen-Activated Gq-Coupled
5-HT2A Serotonin Receptor Cell 2020 182 1574 1588 10.1016/j.cell.2020.08.024 PMC7593816 32946782

Wacker D. Wang S. McCorvy J. D. Crystal Structure of
an LSD-Bound Human Serotonin Receptor Cell 2017 168 377 389 10.1016/j.cell.2016.12.033 PMC5289311 28129538

Pogorelov , V. M. ; Rodriguiz , R. M. ; Roth , B. L. ; Wetsel , W. C. The G protein
biased serotonin 5-HT 2A receptor agonist lisuride exerts anti-depressant
drug-like activities in mice bioRxiv 2023 10.1101/2023.06.01.543310 .PMC10603247 37900918

Moliner R. Girych M. Brunello C. A. Psychedelics promote
plasticity by directly binding to BDNF receptor TrkB Nat. Neurosci. 2023 26 1032 1041 10.1038/s41593-023-01316-5 PMC10244169 37280397

Cameron L. P. Benetatos J. Lewis V. Beyond the 5-HT2A receptor:
Classic and nonclassic targets in psychedelic drug action J. Neurosci. 2023 43 7472 7482 10.1523/JNEUROSCI.1384-23.2023 PMC10634557 37940583

Bunzow J. R. Sonders M. S. Arttamangkul S. Amphetamine, 3,4-methylenedioxymethamphetamine,
lysergic acid diethylamide, and metabolites of the catecholamine neurotransmitters
are agonists of a rat trace amine receptor Mol. Pharmacol. 2001 60 1181 1188 10.1124/mol.60.6.1181 11723224

Warren A. L. Lankri D. Cunningham M. J. Structural pharmacology
and therapeutic potential of 5-methoxytryptamines Nature 2024 630 237 246 10.1038/s41586-024-07403-2 PMC11152992 38720072

Jing L. Li J.-X. Trace amine-associated receptor 1: A promising target for the treatment
of psychostimulant addiction Eur. J. Pharmacol. 2015 761 345 352 10.1016/j.ejphar.2015.06.019 PMC4532615 26092759

Carbonaro T. M. Gatch M. B. Neuropharmacology of N,N-dimethyltryptamine Brain Res. Bull. 2016 126 74 88 10.1016/j.brainresbull.2016.04.016 PMC5048497 27126737

Hesselgrave N. Troppoli T. A. Wulff A. B. Cole A. B. Thompson S. M. Harnessing
psilocybin: antidepressant-like behavioral and synaptic actions of
psilocybin are independent of 5-HT2R activation in mice Proc. Natl. Acad. Sci. U.S.A. 2021 118 e202248911810.1073/pnas.2022489118 PMC8092378 33850049

de
la Fuente Revenga M. Zhu B. Guevara C. A. Prolonged
epigenomic and synaptic plasticity alterations following single exposure
to a psychedelic in mice Cell Rep. 2021 37 10983610.1016/j.celrep.2021.109836 PMC8582597 34686347

Cameron L. P. Patel S. D. Vargas M. V. 5-HT2ARs Mediate Therapeutic
Behavioral Effects of Psychedelic Tryptamines ACS Chem. Neurosci. 2023 14 351 358 10.1021/acschemneuro.2c00718 PMC9939288 36630260

Maguire D. R. Effects
of 2,5-Dimethoxy-4-Methylamphetamine (DOM) and 2-Piperazin-1-yl-Quinoline
(Quipazine) on Fentanyl Versus Food Choice in Rhesus Monkeys J. Pharmacol. Exp. Ther. 2023 384 155 162 10.1124/jpet.122.001318 PMC9827501 36272734

Salinsky L. Merritt C. R. Anastasio N. C. Cunningham K. A. R-(−)­2,5-dimethoxy-4-iodoamphetamine
[(−)-DOI] decreases cocaine demand in a 5-HT2AR-mediated manner J. Pharmacol. Exp. Ther. 2023 385 310.1124/jpet.122.278820

Martin D. A. Gyawali U. Calu D. J. Effects of 5-HT2A receptor stimulation
on economic demand for fentanyl after intermittent and continuous
access self-administration in male rats Addict.
Biol. 2021 26 e1292610.1111/adb.12926 PMC7688480 32458577

Oppong-Damoah A. Curry K. E. Blough B. E. Rice K. C. Murnane K. S. Effects
of the synthetic psychedelic 2,5-dimethoxy-4-iodoamphetamine (DOI)
on ethanol consumption and place conditioning in male mice Psychopharmacology 2019 236 3567 3578 10.1007/s00213-019-05328-7 PMC6895420 31309240

Shao L.-X. Liao C. Davoudian P. A. Psilocybin’s
lasting action requires pyramidal cell types and 5-HT2A receptors Nature 2025 642 411 420 10.1038/s41586-025-08813-6 PMC12188471 40175553

Cao D. Yu J. Wang H. Structure-based discovery of nonhallucinogenic
psychedelic analogs Science 2022 375 403 411 10.1126/science.abl8615 35084960

Aarrestad I. K. Cameron L. P. Fenton E. M. The psychoplastogen
tabernanthalog induces neuroplasticity without proximate immediate
early gene activation Nat. Neurosci. 2025 28 1919 1931 10.1038/s41593-025-02021-1 PMC12373294 40760185

Saha S. González-Maeso J. The crosstalk between 5-HT2AR and
mGluR2 in schizophrenia Neuropharmacology 2023 230 10948910.1016/j.neuropharm.2023.109489 PMC10103009 36889432

Muir J. Lin S. Aarrestad I. K. Isolation of psychedelic-responsive neurons
underlying anxiolytic behavioral states Science 2024 386 802 810 10.1126/science.adl0666 PMC11588385 39541450

Allen J. A. Halverson-Tamboli R. A. Rasenick M. M. Lipid raft microdomains and neurotransmitter
signalling Nat. Rev. Neurosci. 2007 8 128 140 10.1038/nrn2059 17195035

Allen J. A. Yu J. Z. Dave R. H. Caveolin-1 and lipid
microdomains regulate Gs trafficking and attenuate Gs/adenylyl cyclase
signaling Mol. Pharmacol. 2009 76 1082 1093 10.1124/mol.109.060160 PMC2774991 19696145

Nichols D. E. Hallucinogens Pharmacol. Ther. 2004 101 131 181 10.1016/j.pharmthera.2003.11.002 14761703

Flanagan T. W. Nichols C. D. Psychedelics as anti-inflammatory agents Int. Rev. Psychiatry 2018 30 363 375 10.1080/09540261.2018.1481827 30102081

Cummins B. R. Billac G. B. Nichols D. E. Nichols C. D. 5-HT2A receptors:
Pharmacology and functional selectivity Pharmacol.
Rev. 2025 77 10005910.1016/j.pharmr.2025.100059 PMC12405928 40418878

The Serotonin Receptors ; Roth , B. L. , Ed.; Humana
Press: Totowa, NJ, 2006 ; Vol. 53 , pp 1689 –1699 .

Roth , B. An experiment
in ‘open science’ 2025 https://zendudest.substack.com/p/an-experiment-in-open-science?r=g3vpk&utm_campaign=post&utm_medium=web&triedRedirect=true.

Crombag H. S. Robinson T. E. Drugs, Environment, Brain, and Behavior Curr. Dir. Psychol. Sci. 2004 13 107 111 10.1111/j.0963-7214.2004.00285.x

Siegel S. Evidence from
rats that morphine tolerance is a learned response J. Comp. Physiol. Psychol. 1975 89 498 506 10.1037/h0077058 425

Cummins C. Lyke J. Peak experiences of psilocybin users
and non-users J. Psychoact. Drugs 2013 45 189 194 10.1080/02791072.2013.785855 23909006

Ator N. A. Griffiths R. R. Principles of drug abuse liability
assessment in laboratory animals Drug Alcohol
Depend. 2003 70 S55 72 10.1016/S0376-8716(03)00099-1 12759197

Corne S. J. Pickering R. W. A possible correlation between drug-induced
hallucinations in man and a behavioural response in mice Psychopharmacologia 1967 11 65 78 10.1007/BF00401509 5302272

Corne S. J. Pickering R. W. Warner B. T. A method for assessing
the effects of drugs on the central actions of 5-hydroxytryptamine Br. J. Pharmacol. Chemother. 1963 20 106 120 10.1111/j.1476-5381.1963.tb01302.x PMC1703746 14023050

Halberstadt A. L. Geyer M. A. Effect of hallucinogens on unconditioned
behavior Curr. Top. Behav. Neurosci. 2018 36 159 199 10.1007/7854_2016_466 PMC5787039 28224459

Fantegrossi W. E. Kiessel C. L. Leach P. T. Nantenine:
an antagonist of the behavioral and physiological effects of MDMA
in mice Psychopharmacology 2004 173 270 277 10.1007/s00213-003-1741-2 14740148

Goodwin G. M. Green A. R. A behavioural and biochemical study
in mice and rats of putative selective agonists and antagonists for
5-HT1 and 5-HT2 receptors Br. J. Pharmacol. 1985 84 743 753 10.1111/j.1476-5381.1985.tb16157.x PMC1987141 2580582

Green A. R. O’Shaughnessy K. Hammond M. Schächter M. Grahame-Smith D. G. Inhibition of 5-hydroxytryptamine-mediated
behaviour by the putative 5-HT2 antagonist pirenperone Neuropharmacology 1983 22 573 578 10.1016/0028-3908(83)90147-8 6603593

Colpaert F. C. Janssen P. A. The head-twitch response to intraperitoneal
injection of 5-hydroxytryptophan in the rat: antagonist effects of
purported 5-hydroxytryptamine antagonists and of pirenperone, an LSD
antagonist Neuropharmacology 1983 22 993 1000 10.1016/0028-3908(83)90215-0 6604885

A D. N. Martin B. R. Glennon R. A. Withdrawal from
chronic treatment with (±)-DOI causes super-sensitivity to 5-HT2
receptor-induced head-twitch behaviour in mice Eur. J. Pharmacol. 1990 186 115 118 10.1016/0014-2999(90)94066-7 2282932

Peroutka S. J. Lebovitz R. M. Snyder S. H. Two distinct central
serotonin receptors with different physiological functions Science 1981 212 827 829 10.1126/science.7221567 7221567

Halberstadt A. L. Chatha M. Klein A. K. Wallach J. Brandt S. D. Correlation between the potency of hallucinogens in
the mouse head-twitch response assay and their behavioral and subjective
effects in other species Neuropharmacology 2020 167 10793310.1016/j.neuropharm.2019.107933 PMC9191653 31917152

Fantegrossi W. E. Harrington A. W. Eckler J. R. Hallucinogen-like
actions of 2,5-dimethoxy-4-(n)-propylthiophenethylamine (2C-T-7) in
mice and rats Psychopharmacology 2005 181 496 503 10.1007/s00213-005-0009-4 15983786

Fantegrossi W. E. Harrington A. Kiessel C. Hallucinogen-like
actions of 5-methoxy-N,N-diisopropyltryptamine in mice and rats Pharmacol., Biochem. Behav. 2006 83 122 129 10.1016/j.pbb.2005.12.015 16460788

Lucki I. Nobler M. S. Frazer A. Differential actions
of serotonin antagonists on two behavioral models of serotonin receptor
activation in the rat J. Pharmacol. Exp. Ther. 1984 228 133 139 10.1016/S0022-3565(25)21483-5 6694097

Handley S. L. Singh L. Neurotransmitters and shaking behaviour
 more than a ‘gut-bath’ for the brain? Trends Pharmacol. Sci. 1986 7 324 328 10.1016/0165-6147(86)90371-8

Ortmann R. Bischoff S. Radeke E. Buech O. Delini-Stula A. Correlations between different measures of antiserotonin
activity of drugs. Study with neuroleptics and serotonin receptor
blockers Naunyn-Schmiedeberg’s Arch.
Pharmacol. 1982 321 265 270 10.1007/BF00498511 6132341

Sadzot B. Baraban J. M. Glennon R. A. Hallucinogenic
drug interactions at human brain 5-HT2 receptors: implications for
treating LSD-induced hallucinogenesis Psychopharmacology 1989 98 495 499 10.1007/BF00441948 2505289

Reynolds A. R. Bolin B. L. Stoops W. W. Rush C. R. Relationship
between drug discrimination and ratings of subjective effects: implications
for assessing and understanding the abuse potential of D-amphetamine
in humans Behav. Pharmacol. 2013 24 523 532 10.1097/FBP.0b013e328364505f PMC4058093 23851485

Goodwin A. K. An intravenous self-administration procedure for assessing
the reinforcing effects of hallucinogens in nonhuman primates J. Pharmacol. Toxicol. Methods 2016 82 31 36 10.1016/j.vascn.2016.07.004 27473331

Nichols D. E. Grob C. S. Is LSD toxic? Forensic Sci. Int. 2018 284 141 145 10.1016/j.forsciint.2018.01.006 29408722

Kwan A. C. Olson D. E. Preller K. H. Roth B. L. The neural
basis of psychedelic action Nat. Neurosci. 2022 25 1407 1419 10.1038/s41593-022-01177-4 PMC9641582 36280799

Wulff A. B. Nichols C. D. Thompson S. M. Preclinical perspectives
on the mechanisms underlying the therapeutic actions of psilocybin
in psychiatric disorders Neuropharmacology 2023 231 10950410.1016/j.neuropharm.2023.109504 36921889

Hursh S. R. Galuska C. M. Winger G. Woods J. H. The economics
of drug abuse: a quantitative assessment of drug demand Mol. Interventions 2005 5 20 28 10.1124/mi.5.1.6 15731502

Johnson M. W. Bickel W. K. Replacing relative reinforcing efficacy
with behavioral economic demand curves J. Exp.
Anal. Behav. 2006 85 73 93 10.1901/jeab.2006.102-04 PMC1397796 16602377

Shaham Y. Shalev U. Lu L. de Wit H. Stewart J. The reinstatement model of drug relapse: history, methodology
and major findings Psychopharmacology 2003 168 3 20 10.1007/s00213-002-1224-x 12402102

Maguire D. R. Evaluation of potential punishing effects of 2,5-dimethoxy-4-methylamphetamine
(DOM) in rhesus monkeys responding under a choice procedure Behav. Pharmacol. 2024 35 378 385 10.1097/FBP.0000000000000787 PMC11398979 39052019

Deneau G. Yanagita T. Seevers M. H. Self-administration
of psychoactive substances by the monkey Psychopharmacologia 1969 16 30 48 10.1007/BF00405254 4982648

Johanson C. E. Balster R. L. A summary of the results of a drug
self-administration study using substitution procedures in rhesus
monkeys Bull. Narc. 1978 30 43 54 36945

Yanagita T. Intravenous self-administration of (−)-cathinone
and 2-amino-1-(2,5-dimethoxy-4-methyl)­phenylpropane in rhesus monkeys Drug Alcohol Depend. 1986 17 135 141 10.1016/0376-8716(86)90004-9 3743404

Siegel R. K. Jarvik M. E. DMT self-administration by monkeys
in isolation Bull. Psychon. Soc. 1980 16 117 120 10.3758/BF03334456

Beardsley P. M. Hayes B. A. Balster R. L. The self-administration
of MK-801 can depend upon drug-reinforcement history, and its discriminative
stimulus properties are phencyclidine-like in rhesus monkeys J. Pharmacol. Exp. Ther. 1990 252 953 959 10.1016/S0022-3565(25)20214-2 2181113

Young , A. M. ; Herling , S. ; Woods , J.
H. History of Drug
Exposure as a Determinant of Drug Self-administration . In NIDA Research Monograph ; NIH, 1981 ; Vol. 37 , pp 75 –88 .6798469

Berquist M. D. Fantegrossi W. E. Effects of 5-HT2A receptor agonist
2,5-dimethoxy-4-iodoamphetamine on alcohol consumption in Long-Evans
rats Behav. Pharmacol. 2021 32 382 391 10.1097/FBP.0000000000000628 PMC8266736 33595958

Rijsketic D. R. Casey A. B. Barbosa D. A. UNRAVELing
the synergistic effects of psilocybin and environment on brain-wide
immediate early gene expression in mice. Neuropsychopharmacology 2023 48 1798 1807 10.1038/s41386-023-01613-4 PMC10579391 37248402

Yankelevitch-Yahav R. Franko M. Huly A. Doron R. The forced
swim test as a model of depressive-like behavior J. Visualized Exp. 2015 97 e5258710.3791/52587 PMC4401172 25867960

Cryan J. F. Mombereau C. Vassout A. The tail suspension
test as a model for assessing antidepressant activity: review of pharmacological
and genetic studies in mice Neurosci. Biobehav.
Rev. 2005 29 571 625 10.1016/j.neubiorev.2005.03.009 15890404

Can A. Dao D. T. Terrillion C. E. The tail suspension
test J. Visualized Exp. 2011 e376910.3791/3769 PMC3353516 22315011

Bogdanova O. V. Kanekar S. D’Anci K. E. Renshaw P. F. Factors influencing behavior in the forced swim test Physiol. Behav. 2013 118 227 239 10.1016/j.physbeh.2013.05.012 PMC5609482 23685235

Scheggi S. De Montis M. G. Gambarana C. Making Sense
of Rodent Models of Anhedonia Int. J. Neuropsychopharmacol. 2018 21 1049 1065 10.1093/ijnp/pyy083 PMC6209858 30239762

Becker M. Pinhasov A. Ornoy A. Animal Models of Depression:
What Can They Teach Us about the Human Disease? Diagnostics 2021 11 12310.3390/diagnostics11010123 PMC7830961 33466814

Hibicke M. Nichols C. One dose of psilocybin in late adolescence
mitigates deleterious effects of developmental stress on cognition
and behavioral despair in adult female rats FASEB J. 2020 34 110.1096/fasebj.2020.34.s1.02912

Hibicke M. Kramer H. M. Nichols C. D. A Single Administration
of Psilocybin Persistently Rescues Cognitive Deficits Caused by Adolescent
Chronic Restraint Stress Without Long-Term Changes in Synaptic Protein
Gene Expression in a Rat Experimental System with Translational Relevance
to Depression Psychedelic Med. 2023 1 54 67 10.1089/psymed.2022.0012 PMC11661400 40047006

Rasenick M. M. Depression and Adenylyl Cyclase: Sorting Out the Signals Biol. Psychiatry 2016 80 812 814 10.1016/j.biopsych.2016.09.021 PMC6126898 27968725

Wingo T. S. Liu Y. Gerasimov E. S. Brain proteome-wide association study implicates novel proteins in
depression pathogenesis Nat. Neurosci. 2021 24 810 817 10.1038/s41593-021-00832-6 PMC8530461 33846625

Le-Niculescu H. Roseberry K. Gill S. S. Precision
medicine for mood disorders: objective assessment, risk prediction,
pharmacogenomics, and repurposed drugs Mol.
Psychiatry 2021 26 2776 2804 10.1038/s41380-021-01061-w PMC8505261 33828235

Bhaumik D. K. Wang Y. Yen P.-S. Ajilore O. A. Development
of a Bayesian multimodal model to detect biomarkers in neuroimaging
studies Front. Neuroimaging 2023 2 114750810.3389/fnimg.2023.1147508 PMC10406277 37554638

Tassone V. K. Nezhad F. G. Demchenko I. Rueda A. Bhat V. Amygdala biomarkers of treatment
response in major depressive disorder: An fMRI systematic review of
SSRI antidepressants Psychiatry Res., Neuroimaging 2024 338 11177710.1016/j.pscychresns.2023.111777 38183847

Huang S.-S. Yu Y. H. Chen H. H. Functional
connectivity analysis on electroencephalography signals reveals potential
biomarkers for treatment response in major depression BMC Psychiatry 2023 23 55410.1186/s12888-023-04958-8 PMC10394892 37528355

Tong , X. ; Xie , H. ; Wu , W. Individual Deviations
from Normative Electroencephalographic Connectivity Predict Antidepressant
Response medRxiv 2023 10.1101/2023.05.24.23290434 .PMC10923099 38281595

Murck H. Fava M. Cusin C. Fatt C. C. Trivedi M. Brain ventricle and choroid plexus morphology as predictor
of treatment response in major depression: Findings from the EMBARC
study Brain, Behav., Immun.:Health 2024 35 10071710.1016/j.bbih.2023.100717 PMC10767278 38186634

Vesel C. Rashidisabet H. Zulueta J. Effects
of mood and aging on keystroke dynamics metadata and their diurnal
patterns in a large open-science sample: A BiAffect iOS study J. Am. Med. Inf. Assoc. 2020 27 1007 1018 10.1093/jamia/ocaa057 PMC7647317 32467973

Fujita M. Richards E. M. Niciu M. J. cAMP
signaling in brain is decreased in unmedicated depressed patients
and increased by treatment with a selective serotonin reuptake inhibitor Mol. Psychiatry 2017 22 754 759 10.1038/mp.2016.171 PMC5388600 27725657

Targum S. D. Schappi J. Koutsouris A. A novel peripheral biomarker for depression and antidepressant response Mol. Psychiatry 2022 27 1640 1646 10.1038/s41380-021-01399-1 PMC9106819 34969978

Gunay A. Targum S. D. Leow A. D. Ajilore O. Rasenick M. M. A simple platelet biomarker is associated with symptom
severity in major depressive disorder Mol.
Psychiatry 2025 30 3551 3559 10.1038/s41380-025-02941-1 40038544

Fan L. Zhuang Y. Wu H. Structural basis of
psychedelic LSD recognition at dopamine D1 receptor Neuron 2024 112 3295 3310 10.1016/j.neuron.2024.07.003 39094559

Wacker D. Wang C. Katritch V. Structural
features for functional selectivity at serotonin receptors Science 2013 340 615 619 10.1126/science.1232808 PMC3644390 23519215

Rickli A. Luethi D. Reinisch J. Receptor
interaction profiles of novel N-2-methoxybenzyl (NBOMe) derivatives
of 2,5-dimethoxy-substituted phenethylamines (2C drugs) Neuropharmacology 2015 99 546 553 10.1016/j.neuropharm.2015.08.034 26318099

Ray T. S. Psychedelics and the human receptorome PLoS One 2010 5 e901910.1371/journal.pone.0009019 PMC2814854 20126400

Come citare questo studio

Cameron LP, Johnson MW, Murnane KS, Rasenick MM, Nichols CD. (2026). Next-Generation Psychedelic Drug Development.. ACS chemical neuroscience. DOI: 10.1021/acschemneuro.6c00492

Consulta la pubblicazione originale ↗